Steve has contributed to this thread for quite awhile, and has been a vocal supporter,
and although I do not agree with the negative sentiments that he and some others have
expressed lately, he doesn't deserve
these personal attacks. The stock's price has been disappointing lately, whether
you are a long or short term investor, and at least Steve is being honest in expressing his feelings. There hasn't been any support
on this thread until tonight. Where have you been all this time, Paul? It would be nice if
you guys contributed more than once every six months or only during a crisis. I know you
have posted in the past, but it is not right to come out of the woods and attack someone
who has been one of the few remaining participants as this will destroy whatever effort is left. It takes time and dedication to contribute. If you disagree, you can express yourself without personal attacks.
FYI, there were participants on this thread two years ago like
Richard Harmon, John Metcalf, Bhag, Peter (s), Per, Jay S, James S and others who did predict the success that Viracept would be
and who have always had great respect for the integrity of this
company. I have always found this thread to be a greater source of information, especially at the beginning, than the analysts have been able to provide.
I don't understand why Lind is so impatient for an in-licensing deal, only four months after the Roche deal ended. Agouron said they said they are devoting considerable effort and energy towards licensing a product, and we don't know what stage they are at, as they said they are not in a position now to make any announcements. They aren't going to rush into any deals just to satisfy the street or shareholders.
I agree with Peter, that the less they partner the better, if they can afford to develop drugs through revenues from Viracept. Their cash position is strong now, even with all their expenses. I'm not that anxious for a deal where they end up with royalties of 10-20%, IF they are able to do it without a partner and not have to share the profits later. |
